Event Details

Title: Phase 1/1b Study of the FAK Inhibitor Defactinib (VS-6063) in Combination with Weekly Paclitaxel for Advanced Ovarian Cancer
Abstract #: 937
Date and Time: Sunday, Oct 20, 2013 12:30 PM - 7:30 PM
Session: Poster Session A; Clinical Trials 1
Location: Exhibit Hall C-D

Title: Defactinib (VS-6063) Targets Cancer Stem Cells Directly and Through Inhibition of Tumor-Associated Macrophages and Cytokine Production
Abstract #: 863
Date and Time: Monday, Oct 21, 2013 12:30 PM – 7:30 PM
Session: Poster Session B; Therapeutic Agents: Small Molecule Kinase Inhibitors 2
Location: Exhibit Hall C-D

Title: Malignant Mesothelioma Lacking Merlin Shows Enhances Sensitivity to the FAK Inhibitor Defactinib (VS-6063): Elucidation of the Merlin-FAK Relationship
Abstract #: 765
Date and Time: Tuesday, Oct 22, 2013 12:30 PM – 7:30 PM
Session ID: Poster Session C; Therapeutic Agents: Small Molecule Kinase Inhibitors 3
Location: Exhibit Hall C-D

Title: Merlin Loss as a Biomarker for Defactinib (VS-6063) Sensitivity: High Frequency in Malignant Mesothelioma Tumors
Abstract #: 848
Date and Time: Sunday, Oct 20, 2013 12:30 PM – 7:30 PM
Session ID: Poster Session A; Biomarkers
Location: Exhibit Hall C-D

Title: FAK Inhibitor Defactinib (VS-6063) Enhances the Efficacy of Paclitaxel and Preferentially Targets Ovarian Cancer Stem Cells
Abstract #: 899
Date and Time: Tuesday, Oct 22, 2013 12:30 PM – 7:30 PM
Session ID: Poster Session C; Therapeutic Agents: Small Molecule Kinase Inhibitors 3
Location: Exhibit Hall C-D

Title: Dual mTORC1/2 and PI3K Inhibitor VS-5584 Preferentially Targets Cancer Stem Cells
Abstract #: 889
Date and Time: Monday, Oct 21, 2013 12:30 PM – 7:30 PM
Session ID: Poster Session B; Cancer Stem Cells 2
Location: Exhibit Hall C-D